BACKGROUND: Epithelioid hemangioendothelioma (EH) is a rare neoplasm of vascular origin that may develop at different sites, such as in soft tissue, the lungs, or the liver. It usually affects adult females, and its unpredictable malignant potential has a range between benign hemangioma and clearly malignant hemangioendotheliosarcoma. METHODS: In the current study, the authors describe 2 patients with primary EH of the liver and review 127 previously published cases found in the literature. RESULTS: Most patients presented with nonspecific symptoms, such as right upper quadrant abdominal pain or weight loss. The tumors usually presented as multiple nodular lesions involving both lobes of the liver. Overall metastasis rate was 45.1%, with preferential involvement of the lungs and bones. In general, the key to diagnosis was the demonstration of cells containing factor-VIII-related antigen. CONCLUSIONS: EH of the liver is a very rare clinical entity. The primary treatments of choice are radical hepatic resection or orthotopic liver transplantation. The 5-year survival of 55.5% is significantly better than for other hepatic malignancies.
BACKGROUND: Epithelioid hemangioendothelioma (EH) is a rare neoplasm of vascular origin that may develop at different sites, such as in soft tissue, the lungs, or the liver. It usually affects adult females, and its unpredictable malignant potential has a range between benign hemangioma and clearly malignant hemangioendotheliosarcoma. METHODS: In the current study, the authors describe 2 patients with primary EH of the liver and review 127 previously published cases found in the literature. RESULTS: Most patients presented with nonspecific symptoms, such as right upper quadrant abdominal pain or weight loss. The tumors usually presented as multiple nodular lesions involving both lobes of the liver. Overall metastasis rate was 45.1%, with preferential involvement of the lungs and bones. In general, the key to diagnosis was the demonstration of cells containing factor-VIII-related antigen. CONCLUSIONS: EH of the liver is a very rare clinical entity. The primary treatments of choice are radical hepatic resection or orthotopic liver transplantation. The 5-year survival of 55.5% is significantly better than for other hepatic malignancies.
Authors: Yueyi I Liu; Saghi S Brown; Arvand Elihu; C Andrew Bonham; Waldo Concepcion; Teri A Longacre; Aya Kamaya Journal: Dig Dis Sci Date: 2010-10-30 Impact factor: 3.199
Authors: Joseph Y Chang; Randolph S Marks; David M Nagorney; Schuyler O Sanderson; Sunanda Kane Journal: Therap Adv Gastroenterol Date: 2010-05 Impact factor: 4.409
Authors: Joel A Rodriguez; Natasha S Becker; Christine A O'Mahony; John A Goss; Thomas A Aloia Journal: J Gastrointest Surg Date: 2007-08-21 Impact factor: 3.452
Authors: Bo Ye; Wang Li; Xiang-Yang Liu; Ke-Ling Sun; Long-Hai Yang; Ke Ma; Shou-Hua Zhao; You-Sheng Mao Journal: Med Oncol Date: 2009-03-11 Impact factor: 3.064
Authors: Piotr Remiszewski; Ewa Szczerba; Piotr Kalinowski; Beata Gierej; Krzysztof Dudek; Mariusz Grodzicki; Marcin Kotulski; Rafał Paluszkiewicz; Waldemar Patkowski; Krzysztof Zieniewicz; Marek Krawczyk Journal: World J Gastroenterol Date: 2014-08-28 Impact factor: 5.742